top of page
Coenzyme A overview

Acyl-Coenzyme A Structure, Synthesis, and Metabolic Functions 

Overview of Acyl-CoA Derivatives

Acyl-Coenzyme A (acyl-CoA) derivatives are a diverse family of high-energy thioesters formed by the linkage of a carboxylic acid to the thiol group of Coenzyme A (CoA) [1-4]. Since the discovery of CoA, these compounds have been recognized as the "activated" forms of organic acids, essential for their transport and participation in catabolic and anabolic pathways [3,5]. Conservative estimates suggest that CoA and its thioester derivatives participate in 4% to 9% of all known biochemical reactions in living organisms [1-3,6].

Synthesis and Structure of Acyl-CoA Derivatives 

The formation of an acyl-CoA derivative is an ATP-dependent reaction catalyzed by enzymes known as acyl-CoA synthetases (or CoA ligases) [2,7]. These enzymes activate carboxylic acids by first forming an acyl-adenylate intermediate, which then reacts with the free thiol of CoA’s phosphopantetheine moiety to produce the high-energy thioester bond [4,7-9]. Acyl-CoA synthetases exhibit specificity for carboxylic acids of varying chain lengths:

​

  • Long-chain: 14–20 carbons (e.g., Palmitoyl-CoA)

  • Very long-chain: ≥ 22 carbons [2,9].

 

The large free energy of hydrolysis of the thioester bond serves to "charge" or "activate" the adjoining acyl group for further metabolism [4]. 

Key Acyl-CoA Derivatives and Their Functions in Metabolism 

Acyl-CoA derivatives serve as central metabolic hubs, integrating energy production with macromolecular biosynthesis [2,10,11].

​

  • Acetyl-CoA: The most abundant and central derivative, serving as a critical intermediary in carbon metabolism. It fuels the Tricarboxylic Acid (TCA) cycle for ATP generation and acts as the primary substrate for fatty acid and cholesterol synthesis [2,8,10].

  • Malonyl-CoA: A critical regulator of lipid metabolism; it serves as a substrate for de novo lipogenesis and acts as a potent allosteric inhibitor of carnitine palmitoyltransferase 1 (CPT1), thereby controlling mitochondrial fatty acid uptake and oxidation [2,6,7,11].

  • Succinyl-CoA: An essential intermediate in the TCA cycle and a precursor for heme and porphyrin biosynthesis [2,6,10].

  • HMG-CoA (3-hydroxy-3-methylglutaryl-CoA): A fundamental precursor for cholesterol biosynthesis and the production of ketone bodies (such as 𝛽-hydroxybutyrate) during fasting or starvation [2,10].

  • Crotonyl-CoA: Involved in the oxidation of fatty acids and tryptophan metabolism, this derivative serves as the essential source for protein crotonylation, a post-translational mark that stimulates gene expression more potently than acetylation [5,12].

Clinical Significance of Acyl-CoA Metabolism

Dysregulation of acyl-CoA homeostasis is linked to several severe human pathologies [10,11]. Genetic defects in the CoA biosynthetic pathway cause neurodegenerative disorders such as Pantothenate Kinase-Associated Neurodegeneration (PKAN) and COASY Protein-Associated Neurodegeneration (CoPAN) [10,11,13]. Furthermore, disturbances in acyl-CoA metabolism are implicated in cardiovascular diseases, cancer progression (often involving the upregulation of acetyl-CoA producing enzymes like ACLY and ACSS2), and various myopathies [6,10].

​

Fatty acid oxidation disorders (FAODs), the most common inborn errors of metabolism, highlight the clinical impact of these pathways [14,15]. These autosomal recessive conditions impair the use of fatty acids as an energy source during fasting or increased energy demand. In newborns, FAODs often present early with life-threatening cardiomyopathy, liver failure, and hypoketotic hypoglycemia. They account for 5–8% of cases previously attributed to sudden infant death syndrome [14].

​

Long-chain FAODs (e.g., LCHAD or trifunctional protein deficiency) can also cause maternal complications. Heterozygous mothers carrying affected fetuses are at increased risk of acute fatty liver of pregnancy (AFLP) and HELLP syndrome, likely due to accumulation of toxic fatty acid intermediates from the fetoplacental unit [14,16].

References

  1. Naquet, P.; et al. Regulation of coenzyme A levels by degradation: the ‘Ins and Outs’. Progress in Lipid Research 2020, 78, 101028. 

  2. Yu, Y.; et al. Coenzyme A levels influence protein acetylation, CoAlation and 4′-phosphopantetheinylation. BBA - Molecular Cell Research 2021, 1868(4), 118965. 

  3. Theodoulou, F. L.; et al. Coenzyme A and its derivatives: renaissance of a textbook classic. Biochemical Society Transactions 2014, 42, 1025-1032. 

  4. Semelak, J. A.; et al. Mg2+ binding to coenzyme A. Archives of Biochemistry and Biophysics 2025, 763, 110202. 

  5. Westerveld, M.; Petracca, R. The mystery of crotonyl-CoA. Nature Chemistry 2024. 

  6. Cossin, J. R.; et al. Engineering the Specificity of Acetyl-CoA Synthetase for Diverse Acyl-CoA Thioester Generation. ACS Chemical Biology 2025, 20, 930–941. 

  7. Rakheja, D.; et al. Long-Chain L-3-Hydroxyacyl-Coenzyme A Dehydrogenase Deficiency: A Molecular and Biochemical Review. Laboratory Investigation 2002, 82, 815–824. 

  8. Jones, A. E.; et al. A Single LC-MS/MS Analysis to Quantify CoA Biosynthetic Intermediates and Short-Chain Acyl CoAs. Metabolites 2021, 11, 468. 

  9. Zhang, D.; et al. Coenzyme A in Brain Biology and Neurodegeneration. Biomedicines 2025, 14, 00069. 

  10. Czumaj, A.; et al. The Pathophysiological Role of CoA. International Journal of Molecular Sciences 2020, 21, 9057. 

  11. Xie, J.; et al. The Metabolism of Coenzyme A and Its Derivatives Plays a Crucial Role in Diseases. Frontiers in Bioscience (Landmark Ed) 2024, 29(4), 143. 

  12. Mignani, L.; et al. Coenzyme A Biochemistry: From Neurodevelopment to Neurodegeneration. Brain Sciences 2021, 11(8), 1031. 

  13. Sabari, B. R.; et al. Intracellular Crotonyl-CoA Stimulates Transcription through p300-Catalyzed Histone Crotonylation. Molecular Cell 2015, 58, 203–215. 

  14. Merritt, J. L., II, Norris, M., & Kanungo, S. (2018). Fatty acid oxidation disorders. Annals of Translational Medicine, 6(24), 473. 

  15. Shekhawat, P. S., Matern, D., & Strauss, A. W. (2005). Fetal fatty acid oxidation disorders, their effect on maternal health and neonatal outcome: Impact of expanded newborn screening on their diagnosis and management. Pediatric Research, 57(5), 78R–86R. 

  16. Everard, E., Laeremans, H., Boemer, F., Marie, S., Vincent, M.-F., Dewulf, J. P., Debray, F.-G., De Laet, C., & Nassogne, M.-C. (2024). Impact of newborn screening for fatty acid oxidation disorders on neurological outcome: A Belgian retrospective and multicentric study. European Journal of Paediatric Neurology, 49, 60–65. 

Interested in Acyl-CoA derivatives?

Support your metabolic and enzymatic studies with our range of acyl-CoA products

bottom of page